Featured image: A scientist handles laboratory samples. Contextual photograph; not the FURTHER trial, firmonertinib or samples from its participants. Photo: Julia Koblitz / Unsplash. Unsplash licence.
A change in a cancer gene can matter not just because of where it appears in the genetic code, but because of how it reshapes a protein. A newly published lung-cancer study puts that idea into an early clinical test.
The Cancer Cell paper published on 16 October 2026 reports firmonertinib activity in advanced non-small cell lung cancers carrying a particular group of uncommon EGFR mutations. This is a Phase Ib result, not proof of superiority to established treatment. Some numerical findings had been disclosed before the peer-reviewed publication.
A structural family replaces a simple address
EGFR is a protein that helps transmit growth signals. Certain mutations can make that signalling abnormal. The study focuses on PACC mutations, short for P-loop and alpha-C-helix compressing: changes grouped by their effect on the protein’s three-dimensional shape.
According to MD Anderson’s account of the research, firmonertinib has a chemical feature that helps it bind these altered proteins. Laboratory and tumour-bearing mouse experiments supported the rationale. Those experiments explain why researchers tested the approach; they are separate from the human trial results.
The useful distinction is between a mutation’s address and its consequences. Two alterations near one another in a gene need not create the same drug-binding surface. Conversely, different alterations may produce a sufficiently similar shape to be studied together.
Tumour shrinkage is an early clinical signal
The paper’s indexed abstract describes previously untreated groups of 25 and 22 participants receiving two experimental dose levels. Reported confirmed response rates were 43% and 68%. Median progression-free survival was 11.1 and 16.0 months, respectively.
A response means tumour shrinkage meeting specified assessment criteria. Progression-free survival measures time until worsening or death; it is not the same as overall survival. The reported median also does not mean everyone had the same duration of benefit.
The full PACC programme included 60 patients, according to MD Anderson. That broader enrolment should not be mistaken for the denominator of each first-line result. Keeping the populations separate matters when reading a study that contains several cohorts.
MD Anderson also reports brain-tumour responses in eight of 17 participants with brain metastases. That is encouraging for further investigation, but a small subgroup cannot establish reliable expectations for every patient with cancer in the brain.
Dose comparisons do not settle the treatment comparison
The FURTHER trial registration describes an early-stage development programme. The first-line findings do not include a standard-treatment control that would resolve whether firmonertinib is better than existing options for this population.
The abstract also reports treatment-related dose reductions and discontinuations. These are reminders that an oral targeted drug still has risks. A higher response percentage cannot be read in isolation from tolerability, follow-up and the uncertainty surrounding small groups.
Comparing two experimental doses answers a different question from comparing an experimental medicine with established care. It can help design the next trial without providing the final clinical answer.
A larger trial must test the structural argument
That next comparison is the Phase III ALPACCA study. Its registry, updated on 14 October 2026, lists an estimated 480 participants and compares firmonertinib with osimertinib or afatinib in previously untreated advanced PACC-mutant disease. No results are posted.
The larger study can test whether the early signal survives a controlled comparison. It must also make the balance between benefit and harm clearer. The Phase Ib work was funded by ArriVent BioPharma, according to MD Anderson.
The broader significance is a more precise way to organise uncommon mutations for research. Protein shape may provide a useful bridge between molecular biology and trial design. Whether that bridge leads to better patient outcomes remains a question for the ongoing clinical evidence, not a conclusion supplied by an early response rate.
Reporting and source checks completed on 17 October 2026. By FutureTechDose Editor.
Leave a Reply